STING1 and neoplasm: When cGAS, STING is absent, responses to immunotherapies such as immunosuppressive molecule blockade are weak, and the combination of STING agonists and PD-1 blockers shows stronger antitumor efficacy, and when combined, tumor models that do not respond well to immune checkpoint blockade become sensitized [50].